Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 1/20 | 0.33 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.32 |
| ▸ | FEN1 | P39748 | 2/20 | 0.32 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 2/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | HTR7 | P34969 | 1/20 | 0.31 |
| ▸ | HTR2B | P41595 | 1/20 | 0.31 |
| ▸ | HTR3A | P46098 | 1/20 | 0.31 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.31 |
| ▸ | PDE1B | Q01064 | 2/20 | 0.30 |
| ▸ | RET | P07949 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20202028 | 0.83 | PIK3R1 (0.39) | PIK3R1PIK3CAALOX5APFEN1KDR | |
| SCHEMBL21325503 | 0.81 | FFAR4 (0.33) | RIPK1ALOX5APFEN1HTR2CHTR2B | |
| SCHEMBL21325050 | 0.80 | HTR2B (0.35) | RIPK1ALOX5APFEN1HTR2CHTR7 | |
| SCHEMBL21325056 | 0.76 | ALOX5AP (0.34) | RIPK1ALOX5APFEN1 | |
| SCHEMBL21325060 | 0.75 | ALOX5AP (0.33) | RIPK1ALOX5APFEN1HTR2CHTR7 | |
| SCHEMBL21534011 | 0.73 | HTR2C (0.36) | ALOX5APFEN1HTR2CHTR7HTR2B | |
| SCHEMBL21325058 | 0.72 | FFAR4 (0.35) | RIPK1ALOX5APFEN1 | |
| SCHEMBL21325057 | 0.71 | RIPK1 (0.37) | RIPK1ALOX5APFEN1HTR2CHTR7 | |
| SCHEMBL20202029 | 0.69 | RIPK1 (0.33) | RIPK1ALOX5APFEN1 | |
| SCHEMBL21690529 | 0.68 | ALOX5AP (0.34) | ALOX5APFEN1HTR2CHTR7HTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11247984-B2 | Uracil containing compounds | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2022-02-15 | — | — | US | disclosed |
| US-11174271-B2 | 6-membered uracil isosteres | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2021-11-16 | — | — | US | disclosed |
| US-11014924-B2 | Hydantoin containing deoxyuridine triphosphatase inhibitors | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2021-05-25 | — | — | US | disclosed |
| US-10858344-B2 | Hydantoin containing deoxyuridine triphosphatase inhibitors | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2020-12-08 | — | — | US | disclosed |
| US-20200039966-A1 | URACIL CONTAINING COMPOUNDS | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2020-02-06 | — | — | US | disclosed |
| US-20190330210-A1 | HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2019-10-31 | — | — | US | disclosed |
| US-20190270756-A1 | 6-MEMBERED URACIL ISOSTERES | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2019-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11174271-B2 | 6-membered uracil isosteres | UNG, DUT, DPYD | RIPK1 3321/4885PIK3R1 877/4885PIK3CA 552/4885 |
| US-20190330210-A1 | HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | DUT, TYMP, DPYD | RIPK1 3869/4885PIK3R1 2114/4885PIK3CA 1286/4885 |
| US-10858344-B2 | Hydantoin containing deoxyuridine triphosphatase inhibitors | DUT, TYMP, DPYD | RIPK1 3869/4885PIK3R1 2114/4885PIK3CA 1286/4885 |
| US-11014924-B2 | Hydantoin containing deoxyuridine triphosphatase inhibitors | DUT, TYMP, DPYD | RIPK1 3869/4885PIK3R1 2114/4885PIK3CA 1286/4885 |
| US-20200039966-A1 | URACIL CONTAINING COMPOUNDS | UNG, DPYD, DUT | RIPK1 3431/4885PIK3R1 1268/4885PIK3CA 449/4885 |
| US-11247984-B2 | Uracil containing compounds | UNG, DPYD, DUT | RIPK1 3431/4885PIK3R1 1268/4885PIK3CA 449/4885 |
| US-20190270756-A1 | 6-MEMBERED URACIL ISOSTERES | UNG, DUT, DPYD | RIPK1 3321/4885PIK3R1 877/4885PIK3CA 552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.